nited Kingdom childhood Acute Lymphoblastic Leukaemia Randomised Trial 2003
Phase 3
Completed
- Conditions
- eukaemiaCancerLymphoid leukaemia
- Registration Number
- ISRCTN07355119
- Lead Sponsor
- niversity of Sheffield (UK)
- Brief Summary
2013 results in: http://www.ncbi.nlm.nih.gov/pubmed/23395119 2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/24904116 2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/24924991 2017 retrospective observational analysis in: http://www.ncbi.nlm.nih.gov/pubmed/28982824 2018 results in: http://www.ncbi.nlm.nih.gov/pubmed/29519867 (added 02/08/2019)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 2500
Inclusion Criteria
Children aged 1 - 18 years with ALL
As of 12/02/2010, young adults up to their 25th birthday are also eligible for this trial.
Exclusion Criteria
1. Mature B ALL
2. Infant ALL (aged less than 1 year)
3. Philadelphia positive ALL
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Event-free survival, measured at 5 years
- Secondary Outcome Measures
Name Time Method <br> 1. Survival, measured at 5 years<br> 2. Quality of life, measured at week 1, week 4, start of maintenance treatment, 18 months, end of treatment<br> 3. Complete response (CR) rate measured at 4 weeks<br>